Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11463MR)

This product GTTS-WQ11463MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11463MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14652MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ4315MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ7642MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ4736MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ1924MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ12755MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ2790MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ1672MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW